

Supplementary Table S1. Therapeutic profiles of CCRT followed by durvalumab consolidation

| Chemoradiotherapy phase | | n, (%) |
|---|---------------------------------|---------------|
| Radiotherapy | Median total radiation, (range) | 60 Gy (45-60) |
| | Median total fraction, (range) | 30 Fr (15-30) |
| Chemotherapy regimen | Weekly CBDCA+PTX | 12 (40) |
| | Low dose CBDCA | 7 (23.3) |
| | CDDP+DTX | 3 (10) |
| | CBDCA+PTX | 3 (10) |
| | CDDP+S-1 | 3 (10) |
| | CDDP+PEM | 1 (3.3) |
| | CDDP+ETP | 1 (3.3) |
| Durvalumab consolidation phase | | |
| Completion or withdrawal of durvalumab administration | Completion of durvalumab | 10 (33.3) |
| | Discontinuation due to AEs | 3 (10) |
| | Discontinuation due to PD | 16 (19.7) |
| | Others | 1 (3.3) |

CCRT, concurrent chemoradiotherapy; Gy, gray; Fr, fractions; CBDCA, carboplatin; PTX, paclitaxel; CDDP, cisplatin; DTX, docetaxel; PEM, pemetrexed; ETP, etoposide; AE, adverse event; PD, progressive disease.